Bibera Gyneth Lourdes G, San Martin Peter, van Oorschot Desiree A M, Hidayati Afif Nurul, Permatasari Deliana, Sri La Sri Ponnampalavanar Sasheela, Govinden Kughan, Batac Maria Christina Filomena, Javier Joselito, Tantawichien Terapong, Boonmahittisut Phatu, Trang Trinh Minh, Dang Thi Thanh Tuyen
GSK, Taguig City 1634, Philippines.
GSK, 1300 Wavre, Belgium.
Vaccines (Basel). 2024 Dec 19;12(12):1433. doi: 10.3390/vaccines12121433.
The burden of herpes zoster (HZ) is recognized worldwide; however, there is seemingly limited information on incidence and vaccination practices in Southeast Asia (SEA). A scientific workshop was held by the Zoster Experts' Network to exchange and consolidate insights on the burden of HZ and the patient pathway in SEA. The workshop included practicing clinical experts and public health specialists/epidemiologists from Indonesia, Malaysia, the Philippines, Thailand, and Vietnam. It aimed to identify gaps in the literature, outline patient pathways, and evaluate HZ vaccine recommendations among these countries. Consensus was identified on the substantial lack of epidemiological data on HZ in SEA and the need to investigate the impact of age, immunocompromising conditions, and comorbidities on the incidence and severity of HZ in the region. However, available data in SEA did indicate a rising disease and socioeconomic burden of HZ, with concerns that current treatment strategies for HZ are suboptimal. The HZ patient pathways generated by the experts highlighted common themes and differences between the five countries. Furthermore, the experts highlighted the lack of awareness of HZ and its impact on patients' quality of life, among patients and healthcare professionals. Evaluation of the current local HZ vaccine recommendations further showed differences in age and the inclusion of at-risk populations between countries. The workshop outcomes emphasize the need for further HZ surveillance in SEA. Efforts to align and address leakage within the patient pathway and raise awareness on the impact of HZ should be prioritized. Awareness initiatives and alignment on vaccine recommendations are also needed.
带状疱疹(HZ)的负担在全球范围内都得到了认可;然而,东南亚(SEA)关于发病率和疫苗接种情况的信息似乎有限。带状疱疹专家网络举办了一次科学研讨会,以交流和整合关于东南亚HZ负担及患者就医流程的见解。该研讨会邀请了来自印度尼西亚、马来西亚、菲律宾、泰国和越南的临床执业专家以及公共卫生专家/流行病学家。其目的是找出文献中的空白,勾勒患者就医流程,并评估这些国家的HZ疫苗建议。会上达成的共识是,东南亚地区严重缺乏关于HZ的流行病学数据,有必要调查年龄、免疫功能低下状况和合并症对该地区HZ发病率和严重程度的影响。然而,东南亚现有的数据确实表明HZ的疾病负担和社会经济负担在不断上升,人们担心目前针对HZ的治疗策略并不理想。专家们总结出的HZ患者就医流程凸显了这五个国家的共同主题和差异。此外,专家们强调,患者和医疗保健专业人员对HZ及其对患者生活质量的影响缺乏认识。对当前当地HZ疫苗建议的评估进一步显示,各国在年龄以及高危人群纳入方面存在差异。研讨会的成果强调了在东南亚地区进一步开展HZ监测的必要性。应优先努力调整并解决患者就医流程中的漏洞,并提高对HZ影响的认识。还需要开展提高认识的举措并统一疫苗建议。